Semaglutide (Ozempic) linked to fewer bone fractures despite greater weight loss

A large real-world study suggests semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected bonus for people with type 2 diabetes: stronger protection against bone fractures while delivering greater weight loss. Researchers analyzing health records from nearly 60,000 adults found that people taking semaglutide experienced about 15% fewer fractures than those using other common weight-loss medications, despite losing more weight.

This report comes from ScienceDaily. The story centres on Semaglutide (Ozempic) linked to fewer bone fractures despite greater weight loss. Full coverage and background context is available at the original source. Readers seeking more detail on this developing topic are encouraged to follow updates from ScienceDaily and related outlets covering this beat.